1차 출처 기록
결정급임상시험 등록 변경
Aardvark, ARD-101의 PWS 대상 3상 HERO 시험 일시 중단
The company voluntarily paused enrollment and dosing in the Phase 3 HERO and OLE trials of ARD-101 after reversible cardiac observations in a healthy-volunteer study. It is working with the FDA to determine next steps and expects to provide further guidance in Q2 2026. ARD-201 development was also paused.
핵심 사실
출처 발췌
EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates ARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates.